Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival in Patients with Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, investigating KEYTRUDA, Merck's anti-PD-1...

Related Keywords

Canada ,Rome ,Lazio ,Italy ,United States ,Gursel Aktan ,Domenica Lorusso ,Data Monitoring Committee ,Foundation Inc ,Catholic University ,European Network For Gynaecological Oncology Trial ,Merck Research Laboratories ,Gynaecological Oncology Trial ,Important Safety Information ,Fatal Immune Mediated Adverse ,News Publishing ,Markets ,